RESUMEN
Anorexigenic substances released during infection may hinder the therapeutic efficacy of in-feed antibiotics. Paracetamol (acetaminophen; PARA) inhibits the anorexia of infection and seems to improve the clinical efficacy of doxycycline (DOX) against bacterial respiratory disease in swine herds. In order to verify whether PARA selectively stimulates intake of DOX-medicated feed in diseased pigs, we documented the pharmacokinetics (PK) of DOX when coadministered with PARA and examined the effect of in-feed PARA on the interindividual variability in plasma concentrations after systemic exposure to in-feed DOX in swine herds with respiratory disease. Systemic exposure to DOX was measured with the area under the curve (AUC) of its plasma concentrations over time. First, a rich-sampling PK study of in-feed and i.v. DOX (10 mg/kg of BW) and PARA (30 and 10 mg/kg of BW, respectively) was performed on 5 pigs. The PK profiles of in-feed DOX were used in mathematical simulations to determine 5 optimal sampling times for the farm-based population PK study. A randomized, blind, parallel PK study was performed in 2 herds with bacterial respiratory disease, where liquid feed was fortified with DOX alone (5 mg x kg of BW(-1) x meal(-1)) or combined with PARA (15 mg x kg of BW(-1) x meal(-1)). Medicated meals were given twice, 12 h apart, to group-housed growing pigs (n > 50 pigs x treatment(-1) x herd(-1), totaling 215 pigs). Plasma concentrations of DOX and PARA were measured with HPLC. At variance with our expectations, PARA decreased (P = 0.069) mean AUC of in-feed DOX and did not decrease its variability (P > 0.34). Mean AUC of DOX increased with feed intake and with initial exposure to DOX, and was greater in sick animals. Therefore, symptomatic PARA-induced improvement in bacterial respiratory disease control with DOX is more likely caused by its analgesic/antipyretic effects than by its orexigenic effect. Interindividual variation in the AUC of DOX was large in pigs given group medication, even when sufficient feeding space was allowed and the amount of feed offered was greater than their requirements. Therefore, future studies to improve the efficacy of group antibiotic therapy should focus on feeding behavior characteristics as well as biopharmaceutical properties of medicated feeds.
Asunto(s)
Acetaminofén/farmacocinética , Analgésicos/farmacocinética , Antibacterianos/farmacocinética , Doxiciclina/farmacocinética , Porcinos/metabolismo , Acetaminofén/sangre , Acetaminofén/farmacología , Analgésicos/sangre , Animales , Antibacterianos/sangre , Antibacterianos/farmacología , Apetito/efectos de los fármacos , Área Bajo la Curva , Doxiciclina/sangre , Doxiciclina/farmacología , Interacciones Farmacológicas , Conducta Alimentaria/efectos de los fármacos , Femenino , Masculino , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/microbiología , Infecciones del Sistema Respiratorio/veterinaria , Enfermedades de los Porcinos/tratamiento farmacológicoRESUMEN
Enrofloxacin and marbofloxacin are two veterinary fluoroquinolones used to treat severe bacterial infections in horses. A repeated measures study has been designed to compare their pharmacokinetic parameters, to investigate their bioavailability and to estimate their absorbed fraction and first-pass effect by using plasma, urinary and metabolite data collected from five healthy mares. Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively). Variance of the AUC(0-inf) of marbofloxacin was lower than that for enrofloxacin, with, respectively, a CV = 15% and 26% intravenously and a CV = 31% and 55% after oral administration. Mean oral bioavailability was not significantly different between marbofloxacin (59%) and enrofloxacin (55%). The mean percentage of the dose eliminated unchanged in urine was significantly higher for marbofloxacin (39.7%) than that for enrofloxacin (3.4%). Absorbed fraction and first-pass effect were only determinable for enrofloxacin, whereas the percentage of the dose absorbed in the portal circulation was estimated to be 78% and the fraction not extracted during the first pass through the liver was 65%. Consequently, the moderate observed bioavailability of enrofloxacin appears to be mainly caused by hepatic first-pass effect.
Asunto(s)
Antiinfecciosos/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Fluoroquinolonas/farmacocinética , Quinolonas/farmacocinética , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/metabolismo , Área Bajo la Curva , Disponibilidad Biológica , Ciprofloxacina/metabolismo , Ciprofloxacina/farmacocinética , Enrofloxacina , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/metabolismo , Femenino , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/metabolismo , Semivida , Caballos , Inyecciones Intravenosas , Quinolonas/administración & dosificación , Quinolonas/metabolismoRESUMEN
Evaluation of skeletal muscle tolerance during development of new drug formulations for i.m. use is most often based on terminal methods performed in the target species after slaughtering. The objective of this study was to evaluate the effect of muscle damage on the pharmacokinetic parameters of the drug delivered into the muscle using an alternative, noninvasive method. Phenylbutazone (PBZ) was used as the test article. Six ewes received increasing volumes of a 20% PBZ i.m. formulation, according to a cross-over design, and an i.v. bolus of the same formulation. Serial blood samples were taken, and a pharmacokinetic analysis of the plasma activity of creatine kinase and plasma PBZ concentrations was carried out. The amount of muscle damage after i.m. administration of 2, 4, or 8 mL of PBZ, calculated from the area under the curve of plasma creatine kinase across time was 36, 76, and 178 g for a 70-kg ewe. The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL. The plasma clearance of PBZ (i.v.) was 4.2 +/- 0.94 mL.kg(-1).h(-1). In conclusion, the absolute bioavailability of PBZ after i.m. administration was not altered by the increased volume of formulation administered despite the overall increase in the extent of muscle damage.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Fenilbutazona/administración & dosificación , Fenilbutazona/efectos adversos , Ovinos , Animales , Antiinflamatorios no Esteroideos/farmacocinética , Disponibilidad Biológica , Química Farmacéutica , Creatina Quinasa/sangre , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Femenino , Semivida , Inyecciones Intramusculares , Músculo Esquelético , Fenilbutazona/farmacocinética , Distribución AleatoriaRESUMEN
Daily urinary collection and assessment of glomerular filtration rate (GFR) and effective renal plasma flow were performed in ten 2-month-old Beagle puppies and ten 6-9 year-old Beagle dogs to identify age-associated differences in renal function. The most striking differences in puppies compared to mature dogs were a higher daily urinary volume (+65%), GFR (+87%), free water reabsorption (+159%), a lower daily protein excretion (-88%), and fractional excretion of phosphorus (-35%). Renal function in Beagle puppies, but not mature dogs, was also quite different compared to data published in younger adult dogs.
Asunto(s)
Perros/fisiología , Riñón/fisiología , Envejecimiento/fisiología , Animales , Calcio/orina , Cloro/orina , Creatinina/orina , Perros/orina , Femenino , Pruebas de Función Renal/veterinaria , Masculino , Fósforo/orina , Potasio/orina , Valores de Referencia , Sodio/orina , Urinálisis/veterinariaRESUMEN
1. The loss of metabolic capacities during culture time constitutes a major limitation for the use of hepatocyte primary cultures in in vitro metabolism measurements. A new strategy is presented that permits one to calculate the Michaelis-Menten parameters V(max) and K(m) from extended experiments, by modelling V(max) as a variable dependent on time using exponential or sigmoidal equations. 2. This method was tested with cortisol depletion in cultured rat hepatocytes. V(max) and K(m) were used to calculate intrinsic clearance, and comparisons were made with methods already described in the literature. Intrinsic clearances given by our method were scaled to in vivo hepatic clearances that were close to those reported in the literature. 3. Our method could quantify the V(max) decrease with culture time from estimates of time parameters, t(1/2) or t(50). In our system, this V(max) decrease was in agreement with P450 cytochrome inactivation rates published for the rat liver. 4. In conclusion, we propose a convenient, simple and useful general method for both Michaelis-Menten parameter estimation and modelling of variations in the metabolic capacities observed in in vitro systems. Such an approach should improve the usefulness of hepatocytes in primary cultures for long-term metabolism experiments.
Asunto(s)
Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Animales , Antiinflamatorios/farmacología , Área Bajo la Curva , Supervivencia Celular , Células Cultivadas , Hidrocortisona/farmacología , Cinética , Masculino , Modelos Químicos , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
The mean (sd) concentration of plasma 20beta-dihydrocortisol in 126 scrapie-affected sheep was 5-5 (7.0) ng/ml compared with 1.1 (0.7) ng/ml in 52 healthy sheep. The mean (sd) concentration of creatinine in the urine of 93 scrapie-affected sheep was 2.43 (1.56) microg/ml compared with 0.94 (0.86) pg/ml in 49 healthy sheep and 1.10 (0-95) pg/ml in 25 sheep with other diseases. These discriminant analyses carried out on healthy and scrapie-affected sheep showed that plasma 20beta-dihydrocortisol and urinary creatinine were the best predictors of the disease, and classified correctly 98 per cent of healthy sheep and 82 per cent of scrapie-affected sheep.
Asunto(s)
Creatinina/orina , Hidrocortisona/análogos & derivados , Hidrocortisona/sangre , Scrapie/diagnóstico , Animales , Biomarcadores/sangre , Biomarcadores/orina , Estudios de Casos y Controles , Femenino , Pruebas Hematológicas/normas , Pruebas Hematológicas/veterinaria , Masculino , Valor Predictivo de las Pruebas , Embarazo , Scrapie/sangre , Scrapie/orina , Ovinos , Urinálisis/normas , Urinálisis/veterinariaRESUMEN
OBJECTIVES: To investigate and validate noninvasive methods for the quantitative evaluation of postinjection muscle damage. ANIMALS: 5 adult sheep. PROCEDURES: Muscle lesions were induced twice in the lumbar region of the longissimus dorsi muscles (2 sides) by IM administration of a 20% formulation of long-acting oxytetracycline (20 mg/kg of body weight). Clinical signs and local cutaneous temperature above the injection site were recorded. Muscle lesions were quantitatively evaluated by ultrasonography and by use of pharmacokinetic analysis of plasma creatine kinase activity, and both were compared with a comprehensive planimetric computer-assisted analysis of the injection sites after euthanasia. RESULTS: Transient cutaneous hypothermia (temperature change, -3.9+/-0.62 C) and subsequent persistent hyperthermia (3.1+/-1.35 C) were observed after the administrations. Despite coefficient of variation < 10% for precision of ultrasonographic measurement of normal muscle, measurements of the lesions, with coefficient of variation > 60% for precision, were systematically underestimated. Quantitative evaluation of muscle damage by use of pharmacokinetic analysis of creatine kinase (12.1+/-4.96 g) was in agreement with results of macroscopic planimetric evaluation (10.8+/-3.64 g). CONCLUSIONS AND CLINICAL RELEVANCE: Ultrasonography cannot be used for quantitative assessment of postinjection muscle damage. Pharmacokinetic analysis of creatine kinase provides an accurate quantitative evaluation of macroscopic muscle damage after IM administration of drugs.
Asunto(s)
Creatina Quinasa/sangre , Músculo Esquelético/lesiones , Ovinos/lesiones , Animales , Antibacterianos/farmacología , Femenino , Inyecciones Intramusculares/veterinaria , Músculo Esquelético/diagnóstico por imagen , Músculo Esquelético/enzimología , Músculo Esquelético/patología , Oxitetraciclina/farmacología , Ovinos/sangre , Ovinos/fisiología , Temperatura Cutánea/fisiología , UltrasonografíaRESUMEN
OBJECTIVE: To assess the effects of moderate exercise on plasma creatine kinase (CK) pharmacokinetics and to estimate exercise-induced muscle damage in dogs. ANIMALS: 6 untrained adult Beagles. PROCEDURE: The study was divided into 3 phases. In phase 1, dogs ran for 1 hour at a speed of 9 km/h, and samples were used to determine the area under the plasma CK activity versus time curve (AUC) induced by exercise. In phases 2 and 3, pharmacokinetics of CK were calculated in dogs during exercise and at rest, respectively. Values for AUC and plasma clearance (CI) were used to estimate muscle damage. RESULTS: At rest, values for Cl, steady-state volume of distribution (Vdss), and mean retention time (MRT) were 0.32+/-0.02 ml/kg of body weight/min, 57+/-173 ml/kg, and 3.0+/-0.57 h, respectively. During exercise, Cl decreased significantly (0.26+/-0.03 ml/kg/min), MRT increased significantly, (4.4+/-0.97 h), and Vdss remained unchanged. Peak of plasma CK activity (151+/-58.8 U/L) was observed 3 hours after completion of exercise. Estimated equivalent amount of muscle corresponding to the quantity of CK released was 41+/-29.3 mg/kg. CONCLUSION AND CLINICAL RELEVANCE: These results revealed that exercise had a minor effect on CK disposition and that the equivalent amount of muscle damaged by moderate exercise was negligible. This study illustrates the relevance for use of the minimally invasive and quantitative pharmacokinetic approach when estimating muscle damage.
Asunto(s)
Creatina Quinasa/farmacocinética , Perros/sangre , Músculo Esquelético/patología , Condicionamiento Físico Animal/fisiología , Animales , Área Bajo la Curva , Creatina Quinasa/administración & dosificación , Creatina Quinasa/sangre , Perros/fisiología , Femenino , Masculino , Músculo Esquelético/lesiones , Músculo Esquelético/metabolismo , Condicionamiento Físico Animal/efectos adversosRESUMEN
Although gastrointestinal complications are common in patients with renal disease, the effects of renal dysfunction on bowel motility and gut transit times are not well known. We assessed gastrointestinal electromyographic activity, gastric emptying rate, orocolonic transit time, oroanal transit time, and xylose absorption before and after surgically inducing a 66% decrease in glomerular filtration rate in dogs. Moderate renal failure induced no gross or microscopic gastrointestinal lesions but caused a 16-42% increase in gastrointestinal motility indexes. We found a 24% decrease in the propagation velocity of the myoelectrical migrating complex in the duodenojejunal segment, a 30% decrease in phase I duration in duodenal and jejunal regions, a 20% increase in the total irregular electrical activity of the small intestine, and a 22% increase in duration of the meal response in the duodenum and jejunum. Renal failure did not change xylose absorption, gastric emptying rate, and orocolonic transit time but decreased colonic transit time by 38%. The mean weight of feces was increased. These results indicate that moderate renal failure alters duodenojejunal motility and decreases colonic transit time.
Asunto(s)
Colon/fisiología , Motilidad Gastrointestinal/fisiología , Intestino Delgado/fisiología , Insuficiencia Renal/fisiopatología , Animales , Antiinfecciosos/farmacocinética , Perros , Vaciamiento Gástrico/fisiología , Absorción Intestinal/fisiología , Masculino , Sulfapiridina/farmacocinética , Xilosa/farmacocinéticaRESUMEN
The present experiment was designed to determine a dosage regimen (dose, interval of administration) in the dog for nimesulide, a nonsteroidal anti-inflammatory drug with in vitro selectivity for the inhibition of cyclo-oxygenase 2 (Cox-2), using a pharmacokinetic/pharmacodynamic (PK/PD) approach. The PK/PD results were compared with those obtained using a classical dose titration study. In the PK/PD experiment, 11 dogs were subjected to Freund's adjuvant arthritis characterized by permanent hyperthermia. Nimesulide (5 mg/kg, oral route) was tested during the secondary phase of the inflammatory response. In the dose titration study, nimesulide (0, 3, 6 and 9 mg/kg, oral route) was tested in eight other dogs using a reversible urate crystal arthritis in a 4-period crossover design. Different PD endpoints (including lameness assessed by force plate and hyperthermia) were regularly measured during the PK/PD experiment, and plasma samples were obtained to determine the plasma nimesulide concentration. The data were modeled using an indirect effect model. The IC50 of nimesulide for lameness was 6.26 +/- 3.01 microg/mL, which was significantly higher than the EC50 value obtained for antipyretic effect (2.72 +/- 1.29 microg/mL). The ED50 estimated from the classical dose titration study were 1.34 mg/kg (lameness) and 3.0 mg/kg (skin temperature). The PK/PD parameters were used to simulate different dosage regimens (dose, interval of administration). The antipyretic and anti-inflammatory effects were calculated from the model for the recommended dosage regimen (5 mg/kg/24 h). It was apparent from this approach, that this dosage regimen enabled 76% of the theoretical maximal drug efficacy to be obtained for pyresis and 43% for lameness. It was concluded from the comparison of in vivo and in vitro IC50, that nimesulide is a potent NSAID for which some Cox-1 inhibition is required to obtain clinically relevant efficacy.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/farmacocinética , Artritis/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Perros , Sulfonamidas/farmacología , Sulfonamidas/farmacocinética , Administración Oral , Animales , Artritis/tratamiento farmacológico , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Fiebre/tratamiento farmacológico , Fiebre/veterinaria , Adyuvante de Freund/administración & dosificación , Cojera Animal/tratamiento farmacológicoRESUMEN
BACKGROUND: Gene delivery of biologically active molecules to the kidney may have potential therapeutic applications in renal and cardiovascular diseases. Recombinant adenovirus is one of the most efficient vectors for in vivo gene delivery. However, in vivo toxicity at the site of administration has to be evaluated for the successful use of adenovirus-mediated gene transfer. The aim of this study was to document precisely the short-term safety of different routes of intra-renal adenoviral administration and to compare their transduction efficiency. METHODS: Dog puppies were injected with an adenoviral vector expressing the beta-galactosidase reporter gene in both kidneys via three different routes, i.e. intra-renal-ureteral route (IU) and intra-renal-arterial route with (IAC) or without (IA) clamping of the renal vein. Toxicity of viral administration was assayed on day 4 at both physiological and histological levels. Renal samples were monitored for the presence of nuclear beta-galactosidase-expressing cells. RESULTS: All renal physiological parameters (glomerular filtration rate, effective renal plasma flow, and electrolyte excretion fractions) remained stable whatever the route of viral administration. No histological lesion was detected in any of the haematoxylin-eosin-stained kidney sections, and there was no evidence of ischaemia-reperfusion injury in the kidneys subjected to venous clamping. Efficient transgene expression was obtained in dog kidneys following IAC and IU injection of adenoviral vectors. Gene transfer via the IAC route induced gene expression predominantly in the cortical interstitial cells. Retrograde IU adenoviral injection resulted in reduced transduction efficiency compared with the IAC route, with transgene expression occurring mainly in the distal tubular and pyelic epithelial cells. CONCLUSIONS: The two major findings of this study were (i) the absence of acute histological and functional renal alteration following intra-arterial and intra-ureteral injections of adenoviral vectors in both kidneys of healthy dogs, and (ii) the efficiency of transgene expression with specific cellular targeting according to the route of administration.
Asunto(s)
Técnicas de Transferencia de Gen/normas , Riñón , Adenoviridae/genética , Animales , Perros , Eficiencia , Expresión Génica , Vectores Genéticos , Inyecciones , Corteza Renal/metabolismo , Túbulos Renales/metabolismo , Masculino , Arteria Renal , Seguridad , Factores de Tiempo , Transducción Genética , Uréter , beta-Galactosidasa/genética , beta-Galactosidasa/metabolismoRESUMEN
Naturally scrapie-affected ewes present a syndrome of hypercortisolism as evaluated by measuring total plasma cortisol concentrations. The objective of this study was to investigate the plasma protein binding of cortisol and to evaluate the concentration of the biologically active free fraction of cortisol in scrapie-affected ewes. Corticosteroid binding globulin (CBG) binding parameters were evaluated by equilibrium dialysis in 13 naturally scrapie-affected ewes and nine healthy ewes, during two periods of the clinical evolution of the disease. The hypercortisolism of the scrapie-affected ewes was confirmed by a significant increase of the plasma 20 beta-dihydrocortisol and cortisone concentrations, while total cortisol concentrations, obtained from an isolated sample, did not differ between scrapie-affected and control ewes. The scrapie diagnosis was confirmed by histopathology. The CBG maximal capacity (B(max)) was two times lower in scrapie-affected ewes than in healthy ewes (37+/-32 nM and 73+/-28 nM respectively). The dissociation constant K(d) (8.8+/-3.7 nM and 9.8+/-3.0 nM respectively) and the non-specific constant value of binding to albumin (1.13+/-0.18 and 1.14+/-0.23 respectively) did not differ significantly between diseased and control ewes. The significant increased concentrations of CBG-free cortisol (i.e. both albumin-bound and free cortisol fractions) in scrapie-affected ewes indicates that total plasma cortisol concentration is not an appropriate index of pituitary-adrenocortical hyperactivity. In conclusion, ewes with naturally occurring scrapie display a syndrome of hypercortisolism associated with a lower CBG binding capacity which leads to an overexposure of glucocorticoid-sensitive targets to CBG-free cortisol. The physiopathological consequences of this overexposure on the development of the neurodegenerative process in prion disease are discussed.
Asunto(s)
Hidrocortisona/metabolismo , Scrapie/metabolismo , Transcortina/metabolismo , Animales , Unión Proteica , OvinosRESUMEN
The influence of a renal injury on the disposition of benazeprilat, the active moiety of benazepril, and of enalaprilat, the active moiety of enalapril, two angiotensin-converting enzyme (ACE) inhibitors (ACEI), having different routes of elimination in dog was investigated during a mild renal insufficiency obtained by a nephrectomy-electrocoagulation method reducing glomerular filtration rate by approximately 50%. Plasma concentrations of the active moieties were analyzed with a physiologically based model taking into account the binding to ACE (high affinity, low capacity). An influence of renal insufficiency on enalapril disposition was shown with an increase in its plasma concentration, which was correlated to the reduction of the glomerular filtration rate. No such effect was evidenced for benazepril. With the physiologically based model analysis, it was shown that renal impairment led to an increase of the apparent benazeprilat clearance (260%), whereas that of enalaprilat was reduced to 40 to 55%. Renal insufficiency had no significant effect either on the apparent volume of distribution of each drug or on the binding parameters [i.e., maximal binding capacity (B(max)) and affinity (K(d))]. Enalaprilat and benazeprilat inhibitory action on ACE also was evaluated ex vivo. Similar patterns of inhibition were observed for both drugs. Renal injury had no significant influence on the overall effect of benazeprilat, whereas the inhibition effect of enalaprilat was significantly increased. It was concluded that renal insufficiency may have effects on the ACEI disposition but that the measurable active moiety plasma concentration is not the most appropriate endpoint to describe and interpret the consequence of a renal injury on ACEI.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacocinética , Benzazepinas/farmacocinética , Enalapril/farmacocinética , Insuficiencia Renal/metabolismo , Animales , Perros , Femenino , Modelos Biológicos , Profármacos/farmacocinética , Análisis de RegresiónRESUMEN
The objective of this study was to validate a kinetic approach for the simultaneous measurement of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) in the dog. Six healthy male Beagle dogs were randomly assigned in a three-period cross-over study of intravenous bolus administration of iohexol (64.7 mg/kg), PAH (10 mg/kg), and an iohexol/PAH mixture. PAH and iohexol were determined simultaneously by a validated high-performance liquid chromatographic method. The iohexol and PAH data obtained after intravenous administration were analyzed using noncompartmental and bicompartmental approaches. A simplified iohexol plasma clearance was also calculated from the terminal elimination phase of the plasma iohexol concentrations versus time profile. The total plasma clearance values for PAH and exo-iohexol were 13+/-2.3 mL/kg/min and 2.9+/-0.3 mL/kg/min, respectively. No significant (or biologically relevant) effect of coadministration of PAH and iohexol was observed on the pharmacokinetic parameters of either drug. The calculation of simplified plasma clearance led to an overestimation of the true plasma clearance. In conclusion, GFR and ERPF can easily and rapidly be measured in the dog by this approach which is relatively noninvasive.
Asunto(s)
Tasa de Filtración Glomerular/fisiología , Yohexol/farmacocinética , Glomérulos Renales/metabolismo , Flujo Plasmático Renal Efectivo/fisiología , Ácido p-Aminohipúrico/farmacocinética , Animales , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Estado de Conciencia , Perros , Quimioterapia Combinada , Semivida , Inyecciones Intravenosas , MasculinoRESUMEN
The cortisol threshold concentration of 1.0 microg/ml in horse urine adopted by the International Federation of the racing Authorities in 1994 is specific. However, an increase in the sensitivity for the detection of cortisol administration would be helpful. Previous studies have shown that 20beta-dihydrocortisol concentration in urine would be a good indicator of cortisol administration. The purpose of the present work was to estimate the population parameters and the critical values of 20beta-dihydrocortisol and 20beta-dihydrocortisone concentration in urine compared with that of cortisol. Using the same probability (1.1 x 10(-4)) which was used for the establishment of the official cortisol threshold, the critical values of 5000 ng/ml for 20beta-dihydrocortisol and 350 ng/ml for 20beta-dihydrocortisone were obtained. Considering these 2 critical values for 20beta-dihydrocortisol and 20beta-dihydrocortisone, the time during which a horse could be declared positive is significantly increased.
Asunto(s)
Cortisona/análogos & derivados , Doping en los Deportes , Caballos/orina , Hidrocortisona/análogos & derivados , Hidrocortisona/farmacocinética , Administración Oral , Análisis de Varianza , Animales , Cromatografía Líquida de Alta Presión/veterinaria , Cortisona/orina , Femenino , Hidrocortisona/administración & dosificación , Hidrocortisona/orina , Inyecciones Intravenosas/veterinaria , Masculino , Espectrometría de Masas/veterinaria , Condicionamiento Físico Animal , Valores de Referencia , Sensibilidad y EspecificidadRESUMEN
The 24-h pattern of corticoid plasma concentrations was determined in scrapie-affected ewes during the clinical phase of the disease. Twenty one ewes (8 healthy and 13 scrapie-affected ewes) were subjected to 24-h blood sampling sessions. Urine samples were simultaneously obtained during the clinical stage of the disease and in healthy ewes. The scrapie diagnosis was performed by histopathology. Plasma and urinary corticoids were assayed using HPLC methods. Mean plasma and urinary levels of corticoid (cortisol, 20beta-dihydrocortisol cortisone) of scrapie-affected ewes were greater than those observed in healthy ewes. 20Beta-dihydrocortisol appeared to be the main cortisol metabolite in ewes. The intra-individual variations of 20beta-dihydrocortisol plasma concentrations were lower than the corresponding plasma cortisol concentrations due to the dampening effect of the metabolic process on the short term variations of cortisol secretion. This dampening mechanism was amplified in urine, the urinary concentrations integrating cortisol production over the period preceding sampling. For these reasons, 20beta-dihydrocortisol could present a potential interest for a non invasive diagnostic test of transmissible spongiform encephalopathies. The pathophysiological consequences of an excessive exposure to cortisol on development of the neurogenerative process are discussed.
Asunto(s)
Corticoesteroides/sangre , Corticoesteroides/orina , Scrapie/metabolismo , Animales , Encéfalo/patología , Cromatografía Líquida de Alta Presión , Ritmo Circadiano , Cortisona/sangre , Cortisona/orina , Femenino , Hidrocortisona/análogos & derivados , Hidrocortisona/sangre , Hidrocortisona/orina , Scrapie/diagnóstico , Scrapie/patología , OvinosRESUMEN
The pharmacokinetics of benazepril, enalapril, and their active metabolites (benazeprilat and enalaprilat) were compared after a single administration of each product by the oral route at the recommended dosage (0.5 mg/kg for both drugs) in the dog before and after moderate experimental renal impairment. Ten dogs were randomly assigned to 2 groups of 5 animals in a 2-period crossover design for angiotensin-converting enzyme inhibitor administration. Renal failure was surgically induced by right nephrectomy and electrocoagulation of the remaining kidney. Renal mass reduction induced a significant decrease (P < .001) in glomerular filtration rate (GFR) (1.7 +/- 0.3 versus 3.3 +/- 0.7 mL/kg/minute). No significant differences before and after surgery were observed for enalapril and benazepril kinetics. The area under the curve (AUC) for enalaprilat increased after surgery from 23.6 +/- 14.7 to 42.4 +/- 20.9 micrograms.minute/mL (P < .01). Mean peak plasma concentration (Cmax) was increased in the impaired dogs (59.1 +/- 23.3 versus 43.9 +/- 32.9 ng/mL), but this variation was not significant (P > .05). Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05). Multiple regression analysis showed that both GFR and AUC for enalapril were highly significant variables that explained the variation in AUC for enalaprilat (R2 = .86, P < .001) but not for benazeprilat (R2 = .12, P > .05). The results of this study indicate that exposure to enalaprilat, but not to benazeprilat, is increased in dogs with subclinical renal impairment.
Asunto(s)
Benzazepinas/farmacocinética , Enfermedades de los Perros/metabolismo , Enalapril/farmacocinética , Insuficiencia Renal/veterinaria , Administración Oral , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/farmacocinética , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Animales , Área Bajo la Curva , Benzazepinas/administración & dosificación , Benzazepinas/uso terapéutico , Análisis Químico de la Sangre/veterinaria , Cromatografía Líquida de Alta Presión/veterinaria , Medios de Contraste/química , Estudios Cruzados , Enfermedades de los Perros/tratamiento farmacológico , Perros , Enalapril/administración & dosificación , Enalapril/uso terapéutico , Femenino , Cromatografía de Gases y Espectrometría de Masas/veterinaria , Tasa de Filtración Glomerular/efectos de los fármacos , Tasa de Filtración Glomerular/veterinaria , Ácido Yotalámico/química , Distribución Aleatoria , Insuficiencia Renal/complicaciones , Insuficiencia Renal/metabolismoAsunto(s)
Antiinfecciosos/farmacocinética , Enfermedades de los Perros/metabolismo , Fluoroquinolonas , Quinolonas/farmacocinética , Insuficiencia Renal/veterinaria , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/sangre , Enfermedades de los Perros/sangre , Perros , Femenino , Quinolonas/administración & dosificación , Quinolonas/sangre , Insuficiencia Renal/sangre , Insuficiencia Renal/metabolismoRESUMEN
The pharmacokinetics of marbofloxacin was studied in eight healthy female Beagle dogs before and after moderate renal impairment was induced experimentally. A single intravenous (i.v.) administration and repeated administration for 8 days (2 mg/kg, once-a-day) of marbofloxacin were studied. Renal impairment was induced by a right kidney nephrectomy and electrocoagulation of the left kidney. An increase (P < 0.001) in the plasma concentrations of urea (from 3.8+/-0.7 to 9.8+/-2.1 mmol/L) and creatinine (from 78.8+/-3.4 to 145.8+/-22.3 micromol/L), and a significant decrease (2.9+/-0.3 vs 1.5+/-0.2 mL/kg/min) (P < 0.001) in glomerular filtration rate were observed in the renal-impaired dogs. The clearance of marbofloxacin was slightly decreased after the induction of renal failure (1.6+/-0.2 to 1.4+/-0.1 mL/kg/min) (P < 0.05), but no significant variation of volume of distribution at steady state (Vss) and mean residence time (MRT) was observed after intravenous administration of marbofloxacin (P > 0.05). Following oral administration of marbofloxacin, an increase in total area under the concentration time curve (AUC) was observed after renal failure (from 10372+/-1710 to 11459+/-1119 mg x min/L) (P < 0.05), but indices of accumulation were not modified. An increase (P < 0.01) in the AUC of N-oxide-marbofloxacin was observed after surgery. In conclusion, renal impairment has no biologically relevant influence on marbofloxacin disposition and there is no need for dosage adjustment of marbofloxacin in dogs with mild renal impairment.
Asunto(s)
Antiinfecciosos/farmacocinética , Enfermedades de los Perros/metabolismo , Perros/metabolismo , Fluoroquinolonas , Quinolonas/farmacocinética , Insuficiencia Renal/veterinaria , Administración Oral , Animales , Antiinfecciosos/sangre , Área Bajo la Curva , Creatinina/sangre , Perros/sangre , Femenino , Tasa de Filtración Glomerular , Inyecciones Intravenosas/veterinaria , Quinolonas/sangre , Insuficiencia Renal/metabolismo , Urea/sangreRESUMEN
The pharmacokinetic disposition of tolfenamic acid, an NSAID, after a single administration of tolfenamic acid (4 mg kg(-1)) by the intravenous (IV) route was compared in eight dogs before and after a surgically induced renal failure. Renal impairment was confirmed by a significant increase (p <0.001) of water intake, urine volume, and urea and creatinine plasma concentration. PAH and inulin clearances decreased after surgery from 15.2 +/- 4.2 to 9.5 +/- 0.8 mL kg(-1) min(-1) (p < 0.05) and from 4.37 +/- 1.15 to 2.43 +/- 0.88 mL kg(-1) min(-1) (p=0.067),respectively. After surgery, clearance of TA was significantly (p <0.001) increased, from 2.22 +/- 1.68 to 3.59 +/- 1.81 mL kg (-1) min(-1). There was no modification of the steady-state volume of distribution (p > 0.05) and the mean residence time was significantly decreased from 606 +/- 199 to 373 +/- 302 min (p < 0.05). No variation of binding to plasma proteins (> or = 99%) was observed. These results suggest that renal insufficiency could increase hepatic metabolism and/or alter the enterohepatic cycle of TA.